Supernus Pharmaceuticals | SUPN - Equity Capital And Reserves

Stock Price
49.43
Daily Change
-1.77 -3.46%
Monthly
0.43%
Yearly
47.86%
Q2 Forecast
48.44

Supernus Pharmaceuticals reported $1.08B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
Aurora Cannabis CAD 536.36M 30.74M Dec/2025
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Canopy Growth CAD 758.17M 22.16M Dec/2025
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Eisai JPY 889.64B 35.21B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Xeris Pharmaceuticals USD 13.01M 678K Mar/2026